| pubmed-article:17846661 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17846661 | lifeskim:mentions | umls-concept:C0440744 | lld:lifeskim |
| pubmed-article:17846661 | lifeskim:mentions | umls-concept:C0040048 | lld:lifeskim |
| pubmed-article:17846661 | lifeskim:mentions | umls-concept:C0600688 | lld:lifeskim |
| pubmed-article:17846661 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:17846661 | lifeskim:mentions | umls-concept:C0046018 | lld:lifeskim |
| pubmed-article:17846661 | lifeskim:mentions | umls-concept:C1704259 | lld:lifeskim |
| pubmed-article:17846661 | lifeskim:mentions | umls-concept:C1705987 | lld:lifeskim |
| pubmed-article:17846661 | lifeskim:mentions | umls-concept:C1533691 | lld:lifeskim |
| pubmed-article:17846661 | pubmed:dateCreated | 2007-9-11 | lld:pubmed |
| pubmed-article:17846661 | pubmed:abstractText | Sulfur mustard is a well-known blistering chemical warfare agent that has been investigated for its toxicological mechanisms and an efficacious antidote. Since sulfur mustard injury involves dermal:epidermal separation, proteolytic enzymes were suspected to be involved for this separation and eventual blister development. Therefore, protease inhibitors could be of therapeutic utility against sulfur mustard injury. In this study, the effects of Kunitz-domain 1 of human tissue factor pathway inhibitor-2 were evaluated against the toxic effects of 2-chloroethyl ethyl sulfide, a surrogate agent of sulfur mustard. Tissue factor pathway inhibitor-2 is a 32-kDa serine protease inhibitor produced by a variety of cell types including human epidermal keratinocytes, fibroblasts, and endothelial cells. It consists of 3 Kunitz-domains and the first Kunitz-domain contains the putative P(1) residue (arginine at position 24) responsible for protease inhibitory activity. | lld:pubmed |
| pubmed-article:17846661 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17846661 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17846661 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17846661 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17846661 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17846661 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17846661 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17846661 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17846661 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17846661 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17846661 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17846661 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17846661 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17846661 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17846661 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17846661 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17846661 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17846661 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17846661 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17846661 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17846661 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17846661 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17846661 | pubmed:status | PubMed-not-MEDLINE | lld:pubmed |
| pubmed-article:17846661 | pubmed:issn | 1554-0766 | lld:pubmed |
| pubmed-article:17846661 | pubmed:author | pubmed-author:SaxenaAshimaA | lld:pubmed |
| pubmed-article:17846661 | pubmed:author | pubmed-author:ChoiMoonsuk... | lld:pubmed |
| pubmed-article:17846661 | pubmed:author | pubmed-author:ChilukuriNage... | lld:pubmed |
| pubmed-article:17846661 | pubmed:author | pubmed-author:ParikhKalpana... | lld:pubmed |
| pubmed-article:17846661 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:17846661 | pubmed:volume | 7 | lld:pubmed |
| pubmed-article:17846661 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17846661 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17846661 | pubmed:pagination | e2 | lld:pubmed |
| pubmed-article:17846661 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17846661 | pubmed:articleTitle | Protective effects of recombinant kunitz-domain 1 of human tissue factor pathway inhibitor-2 against 2-chloroethyl ethyl sulfide toxicity in vitro. | lld:pubmed |
| pubmed-article:17846661 | pubmed:affiliation | Division of Biochemistry, Department of Molecular Pharmacology, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA. | lld:pubmed |
| pubmed-article:17846661 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17846661 | lld:pubmed |
